Boehringer Ingelheim

[Available On-Demand] ・ Click video to start playback; Join chat Q&A below video
Boehringer Ingelheim
Improving the health of humans and animals is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.
Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2018, Boehringer Ingelheim achieved net sales of around 17.5 billion euros. R&D expenditure of almost 3.2 billion euros, corresponded to 18.1 per cent of net sales.
As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success.
Company Type:
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Germany
Year Founded:
1885
Main Therapeutic Focus:
Lead Product in Development:
NA
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
NA
Speaker
photo
Corp. Sr. Vice President, Bus. Development & Licensing
Boehringer Ingelheim Pharmaceuticals, Inc.